News Releases

Date Title and Summary View
January 13, 2020
– KVD900 Phase 2 Clinical Trial Data Anticipated in Q2 2020 – – KVD824 Selected for Prophylactic Treatment; Phase 2 Expected to Initiate in H2 2020 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 13, 2020-- KalVista Pharmaceuticals, Inc....
Additional Formats